A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib

doi:10.1007/s00432-023-05560-x

	A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib
	Zhong, Nanzhe 1; Yu, Dong 2; Yang, Minglei 1; Lu, Xingyi 3; Zhang, Qiangzu 3; Wei, Wei 1; Jiao, Jian 1; Yang, Xinghai 1; Zhu, Zhi 4; Chen, Su 1; Xiao, Jianru 1
	2024-02-19
发表期刊	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
ISSN	0171-5216
卷号	150 期号:2 页码:9
摘要	PurposeThere is no approved targeted therapy for chordoma at present. Although several preclinical studies have implied the potential applicability of CDK4/6 inhibitor for this rare tumor, no clinical evidence has been documented so far. The purpose of this study was to elucidate the therapeutic efficacy of CDK4/6 inhibitor for chordoma.MethodsThe next generation sequencing (as for whole-exome sequencing, WES assay) and immunohistochemical (IHC) staining of the chordoma tissue from a patient with an advanced lesion were performed before treatment. Then, the patient was treated with Palbociclib for 4 months until progression occurred in the 5th month. Surgical resection was implemented and the tumor tissue was obtained postoperatively for assessment of molecular alterations.ResultsMolecular features of the tumor before medical treatment suggested applicability of CDK4/6 inhibitor and the patient showed partial response (PR) according to Choi Criteria after 4 months treating with Palbociclib until progression occurred. Then, a drastic molecular alteration of the tumor as represented by emergence of dramatic E2F amplification, which is known to induce CDK4/6 independent cell-cycle entry and progression after treatment, was detected. The findings in this patient demonstrated tumor evolution under drug pressure.ConclusionThe findings of the present study suggest the feasibility of Palbociclib for the clinical treatment of chordoma, and imply the necessity of combination therapies rather single drug administration due to the quick resistance of the tumor to Palbociclib treatment.
关键词	Chordoma Palbociclib Genomic features Drug resistance
DOI	10.1007/s00432-023-05560-x
收录类别	SCI
语种	英语
资助项目	The National Natural Science Fund Project of China[82141105] ; The National Natural Science Fund Project of China[81902731] ; National Natural Science Fund Project of China
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:001163925200003
出版者	SPRINGER
引用统计
文献类型	期刊论文
条目标识符	http://119.78.100.204/handle/2XEOYT63/38863
专题	中国科学院计算技术研究所期刊论文_英文
通讯作者	Chen, Su; Xiao, Jianru
作者单位	1.Naval Med Univ, Shanghai Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China 2.Naval Med Univ, Ctr Translat Med, Shanghai 200433, Peoples R China 3.Chinese Acad Sci, State Key Lab Comp Architecture, Inst Comp Technol, Beijing, Peoples R China 4.Naval Med Univ, Changzheng Hosp, Dept Pathol, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Zhong, Nanzhe,Yu, Dong,Yang, Minglei,et al. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,2024,150(2):9.
APA	Zhong, Nanzhe.,Yu, Dong.,Yang, Minglei.,Lu, Xingyi.,Zhang, Qiangzu.,...&Xiao, Jianru.(2024).A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,150(2),9.
MLA	Zhong, Nanzhe,et al."A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib".JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 150.2(2024):9.